Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Parasite used to deliver drugs to the brain
- Researchers are exploring the Toxoplasma gondii parasite as a novel method to deliver drugs directly to the brain, leveraging the parasite’s ability to cross the blood-brain barrier.
- Per Science News, this innovative approach could enhance treatments for brain diseases, offering a new pathway for drug delivery where traditional methods fall short.
FDA officials outline AI lifecycle management
- U.S. Food and Drug Administration officials have detailed a framework for managing the lifecycle of artificial intelligence and machine learning technologies in medical devices, emphasizing the importance of transparency, accountability and continuous monitoring.
- According to MedTech Dive, the guidelines aim to ensure the safety and effectiveness of AI/ML tools, addressing the unique challenges posed by their evolving nature and potential impact on patient care.
BIOSECURE Act could signal a seismic shift for biopharma in U.S. and China
- The BIOSECURE Act has affected U.S. life sciences companies, many of which are already looking to shift their supply sourcing away from China even though the act is not yet law.
- The legislation poses substantial challenges for Chinese biopharma companies, potentially limiting their access to U.S. markets and collaborations, which could affect their growth and innovation capabilities, reports BioSpace.
Pharma says effects of first drug price talks won’t materially affect bottom lines
- Axios reports that drugmakers are telling Wall Street that the initial Medicare drug price negotiations won’t significantly affect their bottom lines in the short run.
- But executives warn that future rounds of negotiations could harm research and development and patient access to new drugs.
Shift in biopharma’s revenue growth from biologics to small molecules
- Biopharma companies are experiencing a shift in revenue growth from biologics to small molecules.
- European Pharmaceutical Review reports that this trend is driven by advancements in small molecule therapies and their increasing market share.
For more insights in life sciences, check out RSM’s industry outlook.
